¼¼°èÀÇ ¸é¿ªÄ¡·áÁ¦ ½ÃÀå : ½ÃÀå ±Ô¸ð, ½¦¾î, µ¿Ç⠺м®(¾àÁ¦À¯Çüº°, ÀûÀÀÁõº°, Áö¿ªº°), ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Immunotherapy Drugs Market Size, Share & Trends Analysis Report By Drug Type (Monoclonal Antibodies, Immunomodulators), By Indication (Infectious Diseases, Cancer), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1632660
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸é¿ªÄ¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è ¸é¿ªÄ¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 5,772¾ï ´Þ·¯¿¡ À̸£¸ç, 2025³âºÎÅÍ 2030³â±îÁö CAGRÀº 13.6%·Î È®´ëµÉ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ÀÌ ¾÷°èÀÇ À¯¸®ÇÑ ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ¿°Áõ¼ºÁúȯ, °¨¿°Áõ µîÀÇ ¸¸¼ºÁúȯ¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í, ÀǾàǰ ½ÂÀο¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø Á¤Ã¥ µîÀÌ ÀÖ½À´Ï´Ù. ¸¸¼º Áúȯ Ä¡·á¿¡ ´ëÇÑ Ç¥Àû Ä¡·áÀÇ Ã¤¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸é¿ªÄ¡·áÁ¦¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ¿¹Ãø ±â°£ µ¿¾È ¾÷°è¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

¿¹¸¦ µé¾î, 2022³â 5¿ù, AstraZeneca Daiichi SankyoÀÇ Enhertu(Æ®¶ó½ºÅõÁÖ¸¿)´Â HER2 ¾ç¼º À¯¹æ¾Ï Ä¡·áÁ¦·Î ¹Ì±¹¿¡¼­ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ´Ù¸¥ Ç¥Àû ¸é¿ª¿ä¹ý ¾à¹°·Î´Â Kadcyla(Æ®¶ó½ºÅõÁÖ¸¿ ¿¥Åº½Å), Tecentriq(¾ÆÅ×Á¹¸®ÁÖ¸¿) µîÀÌ ÀÖ½À´Ï´Ù. 2022³â 6¿ù F. Hofman La Roche´Â NSCLCÀÇ ¼ö¼ú ÈÄ º¸Á¶ Ä¡·áÁ¦·Î TecentriqÀÇ EU ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. °Ô´Ù°¡ ÁßÀú¼Òµæ±¹ÀÇ ÇコÄɾî ÀÎÇÁ¶ó°¡ ¹ßÀüÇϰí ÀÖÀ¸¸ç ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ ¿¬±¸°³¹ßÀÌ È°¹ßÇØÁö°í ÀÖ´Â °ÍÀÌ ¾÷°èÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 12¿ù Novartis AG´Â ¿À½ÃÆç¸®¸¿(BGB-A1217)¿¡ ´ëÇØ BeiGene, Ltd.¿Í Á¦ÈÞÇÏ¿© ¸é¿ªÁ¾¾çÇÐÀÇ ¿¬±¸°³¹ß Ȱµ¿À» È®´ëÇß½À´Ï´Ù.

2021³â 8¿ù, Pfizer, Inc.´Â ¿øÇü Å»¸ðÁõ Ä¡·áÁ¦ ¸®Æ®·¹½ÃƼ´ÕÀÇ 2b/3»ó ÀÓ»ó½ÃÇèÀÇ ÁÁÀº °á°ú¸¦ ¹ßÇ¥Çß½À´Ï´Ù. °Ô´Ù°¡ ¼¼°èÀÇ ¾Ï ÀÌȯÀ² Áõ°¡°¡ ¸é¿ªÄ¡·áÁ¦ ¼ö¿ä¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. GlobocanÀÇ º¸°í¿¡ ÀÇÇϸé, 2020³â¿¡´Â »õ·Ó°Ô 1,930¸¸¸íÀÇ ¾Ï ȯÀÚ°¡ Áø´ÜµÉ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ European Society of Medical Oncology¿¡ µû¸£¸é, À¯·´¿¡¼­ÀÇ ¾Ï ÀÌȯÀ²Àº 2020³âºÎÅÍ 2040³â »çÀÌ¿¡ 21% »ó½ÂÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ¾Ï Ä¡·á¸¦ À§ÇÑ ´Ù¾çÇÑ ¸é¿ªÄ¡·áÁ¦ÀÇ ½ÂÀÎÀº ¾÷°èÀÇ ¼ºÀåÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¸é¿ª¿ä¹ý ¾à¹° ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý¡¤¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¸é¿ªÄ¡·áÁ¦ ½ÃÀå : º¯µ¿ ¿äÀÎ?°æÇâ?¹üÀ§

Á¦4Àå ¸é¿ªÄ¡·áÁ¦ ½ÃÀå : ¾àÁ¦À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ¸é¿ªÄ¡·áÁ¦ ½ÃÀå :ÀûÀÀÁõº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ¸é¿ªÄ¡·áÁ¦ ½ÃÀå :Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Immunotherapy Drugs Market Growth & Trends:

The global immunotherapy drugs market size is estimated to reach USD 577.2 billion by 2030, expanding at a CAGR of 13.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of the industry include increased awareness about chronic diseases including cancer, autoimmune diseases, inflammatory diseases, and infectious diseases, coupled with supportive government policies for drug approval. The rising adoption of targeted therapies for chronic disease treatment is expected to increase inclination toward immunotherapy drugs, thereby driving the industry during the forecast period.

For instance, in May 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab) received U.S. approval for treating HER2-positive breast cancer. Other targeted immunotherapy drugs include Kadcyla (trastuzumab emtansine) and Tecentriq (atezolizumab). In June 2022, F. Hoffmann-La Roche Ltd. received EU approval for Tecentriq as an adjuvant treatment for NSCLC. In addition, developing healthcare infrastructure in low- and middle-income countries coupled with increased research & development by key players is anticipated to contribute to the industry growth. For instance, in December 2021, Novartis AG collaborated with BeiGene, Ltd. for ociperlimab (BGB-A1217), therefore expanding its R&D activities in immune-oncology.

In August 2021, Pfizer, Inc. shared positive results from phase 2b/3 clinical trial of ritlecitinib for treating alopecia areata. Moreover, the rise in the incidence of cancer cases worldwide is expected to drive the demand for immunotherapy drugs. As per Globocan reports, an estimated 19.3 million new oncology cases were diagnosed in 2020. Moreover, according to the European Society of Medical Oncology, cancer incidence in Europe is anticipated to rise by 21% between 2020 and 2040. Thus, approvals of various immunotherapy drugs for cancer treatment are predicted to increase industry growth.

Immunotherapy Drugs Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Immunotherapy Drugs Market Variables, Trends, & Scope

Chapter 4. Immunotherapy Drugs Market: Drug Type Estimates & Trend Analysis

Chapter 5. Immunotherapy Drugs Market: Indication Estimates & Trend Analysis

Chapter 6. Immunotherapy Drugs Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â